PGDx, Illumina Collaborate
News Aug 09, 2016
Personal Genome Diagnostics Inc. (PGDx) has announced an agreement with Illumina, Inc.
to develop two in-vitro diagnostic (IVD) test kits for use on Illumina’s sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples.
Doug Ward, Chief Executive Officer of PGDx, noted, “PGDx currently offers advanced genomic testing services to researchers, drug developers, and physicians and patients through our CLIA-certified laboratory. We now want to apply our expertise to the development of IVD test kits for both tissue and plasma-based samples that will enable other laboratories with next-generation sequencing (NGS) capability to benefit from our broad experience in cancer genomic testing. Illumina is universally recognized as the global leader in NGS platforms, and we are delighted to join forces with them to develop IVD kits for tissue based and liquid biopsy cancer genomic testing.”
“Illumina welcomes the opportunity to work with a diverse set of leading collaborators, such as PGDx, to ensure that patients have access to the IVD tests that best address their needs,” said John Leite PhD, Vice President of Market Development and Product Marketing for Oncology at Illumina. “PGDx is a well-known pioneer in cancer genomics with deep roots in academic medicine.”
PGDx offers a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma based options designed to address the specific research needs of cancer researchers and drug developers. It was established in 2010 by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.
Under the leadership of founders Drs. Luis Diaz and Victor Velculescu, the company has achieved consistent growth by successfully commercializing novel clinical and investigational products and services for researchers, drug developers, molecular testing laboratories and physicians and patients. PGDx’s service offerings for researchers and testing labs are complemented by the clinical services it provides through its CLIA-certified laboratory.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.